<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Endometrial Pathology Cheat Sheet</title>
    <style>
        @page {
            size: landscape;
            margin: 0.5in;
        }
        
        body {
            font-family: Arial, sans-serif;
            font-size: 9pt;
            line-height: 1.3;
            margin: 20px;
        }
        
        h1 {
            text-align: center;
            color: #7c2d12;
            font-size: 20pt;
            margin-bottom: 5px;
        }
        
        .subtitle {
            text-align: center;
            color: #64748b;
            font-size: 10pt;
            margin-bottom: 20px;
        }
        
        table {
            width: 100%;
            border-collapse: collapse;
            margin-bottom: 20px;
            page-break-inside: auto;
        }
        
        th {
            background-color: #7c2d12;
            color: white;
            font-weight: bold;
            padding: 8px;
            border: 2px solid #7c2d12;
            text-align: left;
            font-size: 9pt;
        }
        
        td {
            border: 1px solid #94a3b8;
            padding: 6px;
            vertical-align: top;
            font-size: 8pt;
        }
        
        tr:nth-child(even) {
            background-color: #fef3c7;
        }
        
        tr:nth-child(odd) {
            background-color: #ffffff;
        }
        
        .entity-col {
            font-weight: bold;
            background-color: #fed7aa !important;
            width: 12%;
        }
        
        .clinical-col { width: 15%; }
        .gross-col { width: 13%; }
        .histo-col { width: 15%; }
        .ihc-col { width: 14%; }
        .ddx-col { width: 13%; }
        .pearls-col { width: 18%; }
        
        strong {
            color: #dc2626;
            font-weight: bold;
        }
        
        .key-concepts {
            background-color: #fef3c7;
            border: 2px solid #7c2d12;
            padding: 15px;
            margin-top: 20px;
            page-break-inside: avoid;
        }
        
        .key-concepts h2 {
            color: #7c2d12;
            font-size: 14pt;
            margin-top: 0;
            margin-bottom: 10px;
        }
        
        .key-concepts h3 {
            color: #92400e;
            font-size: 11pt;
            margin-top: 10px;
            margin-bottom: 5px;
        }
        
        .key-concepts ul {
            margin: 5px 0;
            padding-left: 20px;
        }
        
        .key-concepts li {
            margin-bottom: 3px;
            font-size: 9pt;
        }
        
        .footer {
            text-align: center;
            color: #64748b;
            font-size: 8pt;
            margin-top: 20px;
        }
        
        .abbreviations {
            background-color: #dbeafe;
            border: 2px solid #1e40af;
            padding: 10px;
            margin-bottom: 20px;
            font-size: 9pt;
        }
        
        .abbreviations h3 {
            color: #1e40af;
            font-size: 11pt;
            margin-top: 0;
            margin-bottom: 8px;
        }
        
        .abbr-item {
            margin-bottom: 3px;
        }
        
        @media print {
            body {
                margin: 0;
            }
            .no-print {
                display: none;
            }
        }
    </style>
</head>
<body>
    <h1>ENDOMETRIAL PATHOLOGY CHEAT SHEET</h1>
    <div class="subtitle">ABP Gynecologic & Placenta Section: 8% Written, 7% Virtual Microscopy</div>
    
    <button class="no-print" onclick="window.print()" style="position: fixed; top: 10px; right: 10px; padding: 10px 20px; background-color: #7c2d12; color: white; border: none; border-radius: 5px; cursor: pointer; font-size: 12pt; z-index: 1000;">Print/Save as PDF</button>
    
    <div class="abbreviations">
        <h3>KEY ABBREVIATIONS</h3>
        <div class="abbr-item"><strong>SEIC</strong> = Serous Endometrial Intraepithelial Carcinoma | <strong>EIN</strong> = Endometrial Intraepithelial Neoplasia (not commonly used) | <strong>FIGO</strong> = International Federation of Gynecology and Obstetrics grading | <strong>PID</strong> = Pelvic Inflammatory Disease | <strong>IUD</strong> = Intrauterine Device | <strong>MMMT</strong> = Malignant Mixed Mesodermal Tumor</div>
        <div class="abbr-item"><strong>Type I</strong> = Estrogen-dependent, preceded by hyperplasia | <strong>Type II</strong> = NOT estrogen-dependent, preceded by atrophic endometrium</div>
    </div>
    
    <table>
        <thead>
            <tr>
                <th>ENTITY</th>
                <th>CLINICAL</th>
                <th>GROSS</th>
                <th>HISTOLOGY</th>
                <th>IHC/STUDIES</th>
                <th>DDx</th>
                <th>KEY PEARLS</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td class="entity-col">ACUTE ENDOMETRITIS (AR)</td>
                <td class="clinical-col">Associated with PID; may be associated with pregnancy; elevated temperature, leukocytosis, discomfort, pain</td>
                <td class="gross-col">When secondary to PID: tubo-ovarian complex with fibrous adhesions, fibrinous exudate, congestion, edema; associated with IUD use</td>
                <td class="histo-col"><strong>Numerous neutrophils in stroma AND glands</strong>; ectatic blood vessels; fibrin exudate; hemorrhage</td>
                <td class="ihc-col">Tissue Gram stain to identify microorganisms</td>
                <td class="ddx-col">Menstruation: vacuoles in distended glands, decidual change in stroma</td>
                <td class="pearls-col">Clinical history important, particularly as it relates to menstrual cycle; aseptic abortion is a possibility; patient may present with acute abdomen</td>
            </tr>
            
            <tr>
                <td class="entity-col">CHRONIC ENDOMETRITIS (AR)</td>
                <td class="clinical-col">Common; may be asymptomatic or pelvic pain; associated with IUD, PID</td>
                <td class="gross-col">Nonspecific</td>
                <td class="histo-col"><strong>PLASMA CELLS in stroma</strong> (diagnostic); difficult to date; focal crowding mimicking hyperplasia</td>
                <td class="ihc-col">None</td>
                <td class="ddx-col">Hyperplasia: plasma cells unusual; Adenocarcinoma: cribriform/confluent architecture</td>
                <td class="pearls-col">Plasma cells REQUIRED for diagnosis (lymphocytes/neutrophils normally present); diagnosis of hyperplasia with caution if endometritis present</td>
            </tr>
            
            <tr>
                <td class="entity-col">ENDOMETRIAL POLYP (C)</td>
                <td class="clinical-col">Common in middle-aged/postmenopausal women; abnormal bleeding; tamoxifen effect</td>
                <td class="gross-col">Usually solitary, variable size; arises in fundus; pedunculated or sessile</td>
                <td class="histo-col">Irregularly outlined glands out of phase; <strong>fibrovascular stalk with thick-walled vessels</strong>; metaplastic epithelium common</td>
                <td class="ihc-col">None</td>
                <td class="ddx-col">Hyperplasia: diffuse process; Polypoid adenoCA: back-to-back glands, no stroma; Adenosarcoma: atypical stroma</td>
                <td class="pearls-col">Arises from basalis; <0.5% show focal adenoCA confined to polyp; hyperplasia may be confined to polyp; chromosome 6 inversion</td>
            </tr>

            <tr>
                <td class="entity-col">ENDOMETRIAL HYPERPLASIA (C)</td>
                <td class="clinical-col">Middle-aged to postmenopausal; abnormal bleeding; <strong>unopposed estrogen</strong> (obesity, nulliparity, estrogen-producing tumors); PTEN inactivation</td>
                <td class="gross-col">Thickened endometrium; may appear polypoid or normal with velvety surface</td>
                <td class="histo-col"><strong>Increased gland:stroma ratio</strong>; Simple = crowded round/dilated glands; Complex = irregular branching; <strong>Atypia</strong> = nuclear enlargement, hyperchromasia, prominent nucleoli</td>
                <td class="ihc-col">None; atypical hyperplasia more likely aneuploid</td>
                <td class="ddx-col">Proliferative endometrium: even gland distribution; Polyp: focal, thick-walled vessels; Adenocarcinoma: cribriform, back-to-back glands</td>
                <td class="pearls-col"><strong>Atypia vs no atypia</strong> more clinically relevant than simple vs complex; <strong>atypical hyperplasia</strong> = precursor to endometrioid adenoCA; coexists with CA in 25-40%; may respond to progestin</td>
            </tr>

            <tr>
                <td class="entity-col">SEROUS ENDOMETRIAL INTRAEPITHELIAL CARCINOMA (SEIC) (C)</td>
                <td class="clinical-col">Precursor of serous carcinoma; postmenopausal, median age 60; also called "carcinoma in situ"</td>
                <td class="gross-col">None visible</td>
                <td class="histo-col"><strong>Markedly atypical nuclei with prominent nucleoli</strong> identical to invasive serous CA; lines surface/polyps/glands; papillary contour; adjacent endometrium atrophic</td>
                <td class="ihc-col"><strong>p53+</strong>; high Ki-67</td>
                <td class="ddx-col">Serous CA: desmoplasia, confluent pattern, >10mm; Eosinophilic metaplasia: smudged nuclei; Tubal metaplasia: mixed cell types</td>
                <td class="pearls-col">Potential to metastasize widely even WITHOUT stromal invasion; NOT associated with endometrioid CA; lacks desmoplasia/confluent pattern</td>
            </tr>

            <tr>
                <td class="entity-col">ENDOMETRIOID ADENOCARCINOMA (C)</td>
                <td class="clinical-col"><strong>Type I</strong>: obesity, nulliparity, late menopause, unopposed estrogen; preceded by hyperplasia; abnormal bleeding</td>
                <td class="gross-col">Uterus enlarged; single dominant mass, soft, tan-white, friable; endometrium diffusely thickened</td>
                <td class="histo-col">Most common type; crowded complex branching glands with cribriforming/papillary/solid/back-to-back; <strong>FIGO grading</strong>: Grade 1 <5% solid, Grade 2 6-50% solid, Grade 3 >50% solid</td>
                <td class="ihc-col">CK+, vimentin often+, CEA often-, ER/PR+</td>
                <td class="ddx-col">Hyperplasia: stroma between glands; Serous CA: p16+, p53+; Metastatic adenoCA: serosal invasion, history</td>
                <td class="pearls-col">Squamous differentiation NOT prognostically significant; depth of myometrial invasion important prognostic parameter; villoglandular type low grade</td>
            </tr>

            <tr>
                <td class="entity-col">SEROUS CARCINOMA (C)</td>
                <td class="clinical-col"><strong>Type II</strong>: NOT estrogen-dependent; preceded by atrophic endometrium; postmenopausal, age 60s+; abnormal bleeding</td>
                <td class="gross-col">Exophytic tan-pink tumor; superficial myometrial invasion</td>
                <td class="histo-col">Papillary structures with complex branching; <strong>marked nuclear pleomorphism, prominent nucleoli</strong>; hobnail cells; psammoma bodies (30%)</td>
                <td class="ihc-col"><strong>p16 diffuse+, p53 strong+ or null</strong>; WT1 may be+; ER/PR usually-</td>
                <td class="ddx-col">Endometrioid: less atypia, ER/PR+; Clear cell: clear cytoplasm, napsin A+</td>
                <td class="pearls-col"><strong>By definition HIGH GRADE</strong>; poor prognosis; often presents with extrauterine disease; diffuse p16 and aberrant p53 diagnostic</td>
            </tr>

            <tr>
                <td class="entity-col">CLEAR CELL CARCINOMA (F)</td>
                <td class="clinical-col">Usually preceded by atrophic endometrium; women in 60s+; abnormal bleeding</td>
                <td class="gross-col">Similar to endometrioid</td>
                <td class="histo-col">Papillary, glandular, or solid architecture; cells with <strong>abundant clear cytoplasm filled with glycogen</strong>; pleomorphic nuclei; <strong>hobnail cells</strong> (nuclei protrude into lumens)</td>
                <td class="ihc-col"><strong>PAS+ (diastase sensitive)</strong>; ER/PR-, p53-, <strong>napsin A+</strong></td>
                <td class="ddx-col">Serous: p53+, napsin A-; Endometrioid: less clear cytoplasm</td>
                <td class="pearls-col"><strong>By definition HIGH GRADE</strong>; poor prognosis; glycogen in cytoplasm PAS+ but diastase sensitive (vs mucinous)</td>
            </tr>

            <tr>
                <td class="entity-col">ATYPICAL POLYPOID ADENOMYOMA (AR)</td>
                <td class="clinical-col">Late reproductive years; abnormal bleeding; <strong>benign clinical course</strong>; curettage may be curative</td>
                <td class="gross-col">Solitary polypoid mass in lower uterine segment</td>
                <td class="histo-col"><strong>Random glands with irregular outlines in SMOOTH MUSCLE stroma</strong> (short fascicles, few mitoses); atypical epithelium with loss of polarity but no outright pleomorphism; <strong>squamous metaplasia/morules</strong> common</td>
                <td class="ihc-col">p16 stromal expression helps DDx</td>
                <td class="ddx-col">Hyperplasia: diffuse, no smooth muscle; Infiltrating CA: desmoplasia, cribriforming; Carcinosarcoma: malignant spindle component</td>
                <td class="pearls-col">Benign despite atypical appearance; distinguished by <strong>short smooth muscle bundles</strong>; curettage alone may be curative</td>
            </tr>

            <tr>
                <td class="entity-col">ADENOFIBROMA</td>
                <td class="clinical-col">Extremely rare and <strong>benign</strong>; perimenopausal/postmenopausal; abnormal bleeding</td>
                <td class="gross-col">Lobulated polyploid, variable size; tan-brown, hemorrhagic; numerous small cysts on cut surface</td>
                <td class="histo-col">Benign stroma and glands; <strong><4 mitotic figures/10 HPF</strong>; cystic spaces and papillary projections; unremarkable cuboidal/columnar epithelium</td>
                <td class="ihc-col">None</td>
                <td class="ddx-col">Adenosarcoma: atypical stromal cells, mitotic index >5/10 HPF</td>
                <td class="pearls-col">Hysterectomy to prevent recurrence and exclude adenosarcoma</td>
            </tr>

            <tr>
                <td class="entity-col">ADENOSARCOMA (AR)</td>
                <td class="clinical-col">Any age; abnormal bleeding; arises in endometrium (rarely cervix)</td>
                <td class="gross-col">Solitary sessile polypoid mass filling cavity; tan-gray with small cysts, hemorrhage/necrosis</td>
                <td class="histo-col"><strong>LEAFLIKE pattern</strong> (phyllodes-like); <strong>benign epithelium, malignant stroma</strong>; periglandular stromal cellularity; stroma atypical with <strong>4-20 mitoses/10 HPF</strong>; homologous (fibrosarcoma) or heterologous (rhabdomyosarcoma, chondrosarcoma)</td>
                <td class="ihc-col">CK+ epithelium; vimentin+ stroma; desmin/MSA+ if rhabdomyosarcoma; high MIB-1 around glands</td>
                <td class="ddx-col">Adenofibroma: <4 mitoses/10 HPF, bland stroma; Carcinosarcoma: malignant epithelium; Endometrial stromal sarcoma: no leaflike pattern</td>
                <td class="pearls-col">Benign epithelium + malignant stroma; <strong>periepithelial stromal cellularity characteristic</strong>; 20% myometrial invasion; 25-40% recur, 5% metastasize (sarcoma only); sarcomatous overgrowth (â‰¥25%) = worse prognosis</td>
            </tr>

            <tr>
                <td class="entity-col">CARCINOSARCOMA (AR)</td>
                <td class="clinical-col">Postmenopausal; often history of pelvic radiation; abnormal bleeding, pain; bulky tumors protruding through cervical os</td>
                <td class="gross-col">Large friable polypoid mass filling cavity, invading myometrium; variegated with hemorrhage/necrosis; hard foci if heterologous elements (bone/cartilage)</td>
                <td class="histo-col"><strong>MALIGNANT glands (any type adenoCA) + MALIGNANT spindle cells</strong>; homologous (fibrosarcoma, leiomyosarcoma) or heterologous (rhabdomyosarcoma most common, chondrosarcoma, osteosarcoma); hybrid features</td>
                <td class="ihc-col">Vimentin+ both components; CK 8/18+ epithelium, focally+ spindle; desmin/myoglobin+ rhabdomyosarcoma; S-100+ chondro/liposarcoma; CD10+ stromal sarcoma</td>
                <td class="ddx-col">Poorly diff endometrioid CA: lacks biphasic cells; Adenosarcoma: benign epithelium</td>
                <td class="pearls-col">Also called malignant mixed mesodermal tumor (MMMT); early metastases = epithelial; late metastases = sarcomatous overgrowth; lungs common metastatic site; <strong>poor prognosis</strong></td>
            </tr>

            <tr>
                <td class="entity-col">ADENOMYOSIS (C)</td>
                <td class="clinical-col">Nonneoplastic; common in adult women; enlarged uterus, abnormal bleeding, dysmenorrhea; often with leiomyomas; often incidental</td>
                <td class="gross-col">Thickened myometrium with focal soft discolored areas or small cysts</td>
                <td class="histo-col"><strong>Endometrial glands + endometrial stroma within myometrium</strong> >2-2.5mm from basalis; glands often inactive, hemosiderin absent</td>
                <td class="ihc-col"><strong>CD10+ confirms endometrial stroma</strong> (vs smooth muscle)</td>
                <td class="ddx-col">Tangential section: deeper levels show continuity; CA involving adenomyosis: malignant glands with stroma, not myometrial invasion; Invasive adenoCA: desmoplasia</td>
                <td class="pearls-col">Properly oriented section critical (tangential sections mimic adenomyosis); >2-2.5mm from basalis required</td>
            </tr>

            <tr>
                <td class="entity-col">LEIOMYOMA (C)</td>
                <td class="clinical-col">Benign "fibroid"; most common tumor in women and uterus; rare <20y, increasingly common >30y; may cause pain, dysmenorrhea, urinary/bowel changes, infertility</td>
                <td class="gross-col">Often multiple; discrete, well-circumscribed, firm, whorled, tan-white; cystic degeneration in larger tumors; <strong>3 types</strong>: subserosal, intramural, submucosal</td>
                <td class="histo-col">Interlacing fascicles of <strong>bland monomorphic spindle (smooth muscle) cells</strong>; well-circumscribed; <strong><5 mitoses/10 HPF</strong>; pseudocapsule; hyalinization/calcifications may be present</td>
                <td class="ihc-col">Desmin+, SMA+, h-caldesmon+</td>
                <td class="ddx-col">Leiomyosarcoma: >10 mitoses/10 HPF, atypia, necrosis; Cellular leiomyoma: increased cellularity but <5 mitoses; Atypical leiomyoma: atypia but <5 mitoses</td>
                <td class="pearls-col">Benign; treatment often observation or hysterectomy; variants include cellular, atypical, mitotically active, lipoleiomyoma</td>
            </tr>
        </tbody>
    </table>
    
    <div class="key-concepts">
        <h2>KEY CONCEPTS</h2>
        
        <h3>CRITICAL IHC PANELS</h3>
        <ul>
            <li><strong>Endometrioid Adenocarcinoma:</strong> CK+, vimentin often+, ER/PR+ (useful to distinguish from endocervical adenoCA which is vimentin-, CEA+)</li>
            <li><strong>Serous Carcinoma:</strong> p16 diffuse+, p53 strong+ or null, WT1 may be+, ER/PR usually-</li>
            <li><strong>Clear Cell Carcinoma:</strong> PAS+ (diastase sensitive), napsin A+, ER/PR-, p53-</li>
            <li><strong>Adenomyosis:</strong> CD10+ confirms endometrial stroma around glands</li>
            <li><strong>Smooth Muscle:</strong> Desmin+, SMA+, h-caldesmon+</li>
        </ul>
        
        <h3>TYPE I VS TYPE II CARCINOMA</h3>
        <ul>
            <li><strong>Type I (Endometrioid):</strong> Estrogen-dependent, preceded by hyperplasia, obesity/nulliparity/unopposed estrogen, ER/PR+, better prognosis</li>
            <li><strong>Type II (Serous, Clear Cell):</strong> NOT estrogen-dependent, preceded by atrophic endometrium, older age, p53 mutations, ER/PR-, poor prognosis</li>
        </ul>
        
        <h3>ENDOMETRIAL HYPERPLASIA CLASSIFICATION</h3>
        <ul>
            <li><strong>Architecture:</strong> Simple (round/dilated glands) vs Complex (irregular branching)</li>
            <li><strong>Cytology:</strong> Without Atypia vs With Atypia (MORE clinically relevant)</li>
            <li><strong>Clinical Significance:</strong> Atypical hyperplasia = precursor to endometrioid adenoCA; coexists with CA in 25-40%</li>
            <li><strong>EIN terminology:</strong> Occasionally used but NOT commonly adopted</li>
        </ul>
        
        <h3>FIGO GRADING (ENDOMETRIOID ADENOCARCINOMA)</h3>
        <ul>
            <li><strong>Grade 1:</strong> <5% solid (non-squamous, non-morular) areas</li>
            <li><strong>Grade 2:</strong> 6-50% solid areas</li>
            <li><strong>Grade 3:</strong> >50% solid areas</li>
            <li><strong>Note:</strong> Prominent nuclear atypia should raise grade by 1; serous and clear cell are by definition high grade</li>
        </ul>
        
        <h3>ENDOMETRITIS</h3>
        <ul>
            <li><strong>Acute endometritis:</strong> Neutrophils in stroma AND glands; associated with PID, pregnancy; may present with acute abdomen</li>
            <li><strong>Chronic endometritis:</strong> Plasma cells REQUIRED (lymphocytes/neutrophils normally present); associated with IUD, PID</li>
            <li><strong>Diagnosis of hyperplasia with caution if endometritis present</strong></li>
        </ul>
        
        <h3>DIAGNOSTIC PITFALLS</h3>
        <ul>
            <li><strong>Adenomyosis:</strong> Requires properly oriented section; glands >2-2.5mm from basalis; tangential sections can mimic it</li>
            <li><strong>CA involving adenomyosis:</strong> NOT considered myometrial invasion (still surrounded by endometrial stroma)</li>
            <li><strong>Atypical polypoid adenomyoma:</strong> Benign despite atypical appearance; smooth muscle stroma is key</li>
            <li><strong>SEIC:</strong> Can metastasize widely even WITHOUT stromal invasion</li>
        </ul>
        
        <h3>HIGH-YIELD MORPHOLOGY</h3>
        <ul>
            <li><strong>Leaflike/Phyllodes pattern:</strong> Adenosarcoma</li>
            <li><strong>Hobnail cells:</strong> Serous carcinoma, Clear cell carcinoma (nuclei protrude into gland lumens)</li>
            <li><strong>Psammoma bodies:</strong> Serous carcinoma (30% of cases)</li>
            <li><strong>Thick-walled vessels:</strong> Endometrial polyp (diagnostic feature)</li>
            <li><strong>Squamous morules:</strong> Atypical polypoid adenomyoma (very common)</li>
        </ul>
        
        <h3>BENIGN VS MALIGNANT MESENCHYMAL</h3>
        <ul>
            <li><strong>Adenofibroma:</strong> Benign stroma, <4 mitoses/10 HPF</li>
            <li><strong>Adenosarcoma:</strong> Benign epithelium + malignant stroma, 4-20 mitoses/10 HPF, periepithelial cellularity</li>
            <li><strong>Carcinosarcoma:</strong> Malignant epithelium + malignant stroma (both components malignant)</li>
            <li><strong>Leiomyoma:</strong> Bland smooth muscle, <5 mitoses/10 HPF</li>
        </ul>
        
        <h3>MITOTIC RATE CUTOFFS</h3>
        <ul>
            <li><strong><4 mitoses/10 HPF:</strong> Adenofibroma (benign)</li>
            <li><strong>4-20 mitoses/10 HPF:</strong> Adenosarcoma (malignant stroma)</li>
            <li><strong><5 mitoses/10 HPF:</strong> Leiomyoma (benign smooth muscle)</li>
        </ul>
    </div>
    
    <div class="footer">
        
    </div>
</body>
</html>